The immunopathology of sepsis and potential therapeutic targets (Q30234689)

11 June 2017

The immunopathology of sepsis and potential therapeutic targets (English)

1 reference

11 June 2017

0 references

1

Tom van der Poll

1 reference

11 June 2017

4

Mihai G Netea

1 reference

11 June 2017

Frank L van de Veerdonk

series ordinal

2

1 reference

11 June 2017

Brendon P Scicluna

series ordinal

3

1 reference

11 June 2017

language of work or name

1 reference

24 April 2017

1 reference

Nature Reviews Immunology

11 June 2017

1 reference

Sepsis and septic shock: a history.

11 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The ACCP-SCCM consensus conference on sepsis and organ failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Why have clinical trials in sepsis failed?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sepsis: a roadmap for future research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Pattern recognition receptors and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Alarmins: awaiting a clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sepsis: current dogma and new perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Host innate immune responses to sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Role of C5a in inflammatory responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Thrombosis as an intravascular effector of innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

31 March 2020

Coagulation and sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Protease-activated receptors in hemostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Drotrecogin alfa (activated) in adults with septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Neutrophil extracellular traps - the dark side of neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

NETosis: how vital is it?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Endothelial barrier dysfunction in septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sphingosine-1-Phosphate Signaling in Endothelial Disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The role of platelets in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

B cells enhance early innate immune responses during bacterial sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Innate response activator B cells protect against microbial sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immunosuppression in patients who die of sepsis and multiple organ failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Human CD4+CD25+ Regulatory T Lymphocytes Inhibit Lipopolysaccharide-Induced Monocyte Survival through a Fas/Fas Ligand-Dependent Mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Depletion of dendritic cells, but not macrophages, in patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Epigenetic regulation of immune cell functions during post-septic immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Gene-specific control of inflammation by TLR-induced chromatin modifications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Jmjd3 contributes to the control of gene expression in LPS-activated macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Trained immunity: a memory for innate host defense

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Reflex principles of immunological homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A guide to immunometabolism for immunologists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Succinate is an inflammatory signal that induces IL-1β through HIF-1α.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The microbiome and critical illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Hospitalization Type and Subsequent Severe Sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Risk Stratification and Prognosis in Sepsis: What Have We Learned from Microarrays?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A genomic storm in critically injured humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immunotherapy for the Adjunctive Treatment of Sepsis: From Immunosuppression to Immunostimulation. Time for a Paradigm Change?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The Host Response in Patients with Sepsis Developing Intensive Care Unit-acquired Secondary Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

An extracorporeal blood-cleansing device for sepsis therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Monocyte deactivation in septic patients: restoration by IFN-gamma treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immune effects of interferon gamma in persistent staphylococcal sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

New insights into the regulation of T cells by gamma(c) family cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

IL-7 Restores Lymphocyte Functions in Septic Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Harnessing the biology of IL-7 for therapeutic application

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Immunology beats cancer: a blueprint for successful translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Dose-dependent effect of anti-CTLA-4 on survival in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Thymosin alpha 1: past clinical experience and future promise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Ulinastatin and/or thymosin α1 for severe sepsis: A systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Could stem cells be the future therapy for sepsis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

A central role for free heme in the pathogenesis of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sirtuin-2 Regulates Sepsis Inflammation in ob/ob Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Sepsis biomarkers: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Benchmarking the incidence and mortality of severe sepsis in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Long-term cognitive impairment and functional disability among survivors of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Late mortality after sepsis: propensity matched cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.36

Probiotics for preventing ventilator-associated pneumonia

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28436424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Complement System Part II: Role in Immunity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28436424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28436424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRI.2017.36

1 reference

Dimensions Publication ID

11 June 2017

0 references

1 reference